Circulation, Vol 80, 1240-1246, Copyright © 1989 by American Heart Association
JD Rossen, I Simonetti, ML Marcus, P Braun and MD Winniford
Calcium channel antagonists have been shown to blunt maximal coronary flow
after brief coronary occlusion and during pharmacologic coronary dilation
in animals. This property, if present in humans, would result in a
reduction in coronary flow reserve in the absence of intrinsic
abnormalities of the coronary circulation. A reduction of maximal
vasodilator capacity by calcium channel antagonists could also constitute
an important anti-ischemic mechanism of action of these agents. To evaluate
the effect of calcium channel antagonists on coronary flow reserve in awake
humans, we measured coronary flow reserve using the coronary Doppler
catheter and intracoronary papaverine at baseline and after diltiazem
administered by intravenous (125 or 250 micrograms/kg bolus, 5
micrograms/kg/min infusion, n = 8) or intracoronary (150-600 micrograms
bolus, n = 10) routes. Intravenous diltiazem reduced heart rate from 77 +/-
18 to 72 +/- 17 beats/min (mean +/- SD, p less than 0.005) and reduced mean
arterial pressure from 96 +/- 11 to 86 +/- 15 mm Hg (p less than 0.005).
Intravenous diltiazem resulted in a small decrease in coronary flow reserve
(peak- to-resting flow velocity ratio) from 3.9 +/- 1.2 to 3.6 +/- 1.1 (p
less than 0.01). After intracoronary diltiazem, mean arterial pressure was
unchanged (control 99 +/- 12 mm Hg, diltiazem 97 +/- 13 mm Hg), and heart
rate was maintained constant by atrial pacing. Coronary flow reserve was
unchanged at 3.8 +/- 0.9 at baseline and after intracoronary diltiazem.
Thus, treatment with diltiazem does not invalidate the measurement of
coronary flow reserve for diagnostic purposes. Furthermore, these results
suggest that attenuation of maximal coronary dilation by diltiazem is not a
mechanism responsible for its antianginal effects.
ARTICLES
The effect of diltiazem on coronary flow reserve in humans
Cardiovascular Division, University of Iowa College of Medicine, Iowa City.
This article has been cited by other articles:
![]() |
M. Lemma, A. Innorta, M. Pettinari, A. Mangini, G. Gelpi, M. Piccaluga, P. Danna, and C. Antona Flow dynamics and wall shear stress in the left internal thoracic artery: composite arterial graft versus single graft. Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 473 - 478. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Parham, A. Bouhasin, J. P. Ciaramita, S. Khoukaz, S. C. Herrmann, and M. J. Kern Coronary Hyperemic Dose Responses of Intracoronary Sodium Nitroprusside Circulation, March 16, 2004; 109(10): 1236 - 1243. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lemma, A. Mangini, G. Gelpi, A. Innorta, P. Danna, F. Lavarra, E. Piccaluga, and C. Antona Effects of heart rate on phasic Y-graft blood flow and flow reserve in patients with complete arterial myocardial revascularizaton: an intravascular Doppler catheter study Eur. J. Cardiothorac. Surg., July 1, 2003; 24(1): 81 - 85. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Spyrou, M. A. Khan, S. D. Rosen, R. Foale, D. W. Davies, F. Sogliani, R. D. L. Stanbridge, and P. G. Camici Persistent but reversible coronary microvascular dysfunction after bypass grafting Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2634 - H2640. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1989 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |